Overview

L-DEP as an Initial Treatment for EBV-HLH

Status:
Unknown status

Trial end date:
2019-09-01

Target enrollment:

Participant gender:

Summary

This study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as an initial treatment for Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.

Phase:

Phase 3

Details

Lead Sponsor:

Beijing Friendship Hospital

Treatments:

Asparaginase
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Etoposide
Etoposide phosphate
Liposomal doxorubicin
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Pegaspargase
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate